Tubulis raises EUR 308 million to advance ADC therapies and expand its clinical pipeline

The Munich- and Lausanne-based biotech secures Europe’s largest-ever Series C financing to accelerate development of next-generation antibody-drug conjugates.

Tubulis, a biopharmaceutical company specializing in antibody-drug conjugates (ADCs), has raised EUR 308 million in a Series C financing round, Europe’s largest to date for a private biotech and the largest worldwide for an ADC-focused company. The round was led by Venrock Healthcare Capital Partners, with participation from Wellington Management, Ascenta Capital, and existing investors including Nextech Invest, EQT Life Sciences, Frazier Life Sciences, and Andera Partners.

Headquartered in Munich with a new research presence at Lausanne’s Biopôle life sciences campus, Tubulis develops next-generation ADCs that combine targeted drug delivery with superior stability and therapeutic activity. The company’s lead candidate, TUB-040, targets the NaPi2b antigen, which is overexpressed in ovarian cancer and lung adenocarcinoma. It is currently being evaluated in a Phase I/IIa clinical trial (NAPISTAR1-01) and was granted Fast Track designation by the U.S. FDA in 2024.

The new funding will support the expansion of TUB-040 into additional tumor indications and earlier lines of therapy, as well as the clinical advancement of TUB-030, which targets the 5T4 antigen, and several preclinical programs. Tubulis will also continue developing its proprietary ADC platform technologies to unlock new therapeutic applications for cancer treatment.

“This landmark financing reflects strong conviction in Tubulis and the disruptive potential of our ADC platforms,” said Dr. Dominik Schumacher, CEO and Co-founder. “With TUB-040 progressing in the clinic and data forthcoming, we are ready to expand our development programs and bring truly differentiated ADCs to patients.”

A European leader in precision oncology

Founded in 2019, Tubulis is redefining targeted cancer therapy through uniquely matched ADCs that demonstrate durable on-tumor delivery and long-lasting anti-tumor activity. By combining German scientific excellence with Western Switzerland’s collaborative research environment, the company is strengthening Europe’s position in precision oncology.

With this record-breaking financing and a growing footprint at Biopôle, Tubulis joins the ranks of global leaders advancing the next generation of antibody-drug conjugates to improve outcomes for patients with solid tumors.